{"id":33611,"date":"2024-05-24T06:58:03","date_gmt":"2024-05-24T12:58:03","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=33611"},"modified":"2024-05-24T06:58:03","modified_gmt":"2024-05-24T12:58:03","slug":"brakke-viewpoint-may-24-2024","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/","title":{"rendered":"Mirante de Brakke 24 de maio de 2024"},"content":{"rendered":"<p>Esta semana publicamos a \u00faltima edi\u00e7\u00e3o do nosso relat\u00f3rio anual <strong><em>Produtos para controle da dor<\/em><\/strong> relat\u00f3rio. \u00c9 um momento fascinante no segmento de mercado, gra\u00e7as ao lan\u00e7amento em novembro passado do Librela da Zoetis, uma inje\u00e7\u00e3o mensal de anticorpos monoclonais para o tratamento da osteoartrite; e o da Solensia \u2013 o equivalente felino \u2013 no final de 2022.<\/p>\n<p>Esta nova classe de medicamentos para o tratamento da dor tem o potencial de revolucionar o tratamento da dor cr\u00f3nica. A maioria dos veterin\u00e1rios j\u00e1 usa anticorpos monoclonais em pacientes com osteoartrite. Mas com que frequ\u00eancia eles os procuram? S\u00e3o tratamentos independentes ou fazem parte de um protocolo multimodal? Librela substituir\u00e1 completamente o uso de AINEs no tratamento da osteoartrite? Estar\u00e1 a Solensia a criar um novo mercado, tal como a Rimadyl fez quando foi lan\u00e7ada na d\u00e9cada de 1990?<\/p>\n<p>Nosso relat\u00f3rio de produto para controle da dor responde a essas perguntas e muito mais, com feedback direto de nossa pesquisa com 350 veterin\u00e1rios, bem como dados de dispensa\u00e7\u00e3o baseados em PIMS de abril de 2024. Se sua empresa faz parte do mercado de controle da dor em animais de companhia, voc\u00ea n\u00e3o quero perder os insights valiosos deste relat\u00f3rio.<\/p>\n<p><em>Lynn Fondon<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Esta semana publicamos a \u00faltima edi\u00e7\u00e3o do nosso relat\u00f3rio anual sobre produtos para tratamento da dor. \u00c9 um momento fascinante no segmento de mercado, gra\u00e7as ao lan\u00e7amento em novembro passado do Librela da Zoetis, uma inje\u00e7\u00e3o mensal de anticorpos monoclonais para o tratamento da osteoartrite; e o do Solensia \u2013 o equivalente felino \u2013 no final de 2022. Esta nova classe de medicamentos para o tratamento da dor tem o potencial de revolucionar o tratamento da dor cr\u00f3nica. A maioria dos veterin\u00e1rios j\u00e1 usa anticorpos monoclonais em pacientes com osteoartrite. Mas com que frequ\u00eancia eles os procuram? S\u00e3o tratamentos independentes ou fazem parte de um protocolo multimodal? Librela substituir\u00e1 completamente o uso de AINEs no tratamento da osteoartrite? A Solensia est\u00e1 criando um novo mercado, assim como a Rimadyl fez quando foi lan\u00e7ada na d\u00e9cada de 1990? Nosso relat\u00f3rio de produtos para controle da dor responde a essas perguntas e muito mais, com feedback direto de nossa pesquisa com 350 veterin\u00e1rios, bem como dados de dispensa\u00e7\u00e3o baseados em PIMS de abril de 2024. Se sua empresa faz parte do mercado de controle da dor em animais de companhia, voc\u00ea n\u00e3o quero perder os insights valiosos deste relat\u00f3rio. Lynn Fondon<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-33611","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"This week we published the latest edition of our annual Pain Management Products report.\u00a0 It\u2019s a fascinating time in the market segment, thanks to the launch last November of Zoetis\u2019 Librela, a monthly monoclonal antibody injection for treating osteoarthritis; and that of Solensia \u2013 the feline equivalent \u2013 in late 2022. This new class of pain management drugs has the potential to revolutionize the treatment of chronic pain.\u00a0 Most veterinarians are already using monoclonal antibodies in their osteoarthritis patients. But how often are they reaching for them?\u00a0 Are they stand-alone treatments, or part of a multi-modal protocol? Will Librela completely replace the use of NSAIDs in treating osteoarthritis? Is Solensia creating a new market, much like Rimadyl did so when it was launched in the 1990\u2019s? Our Pain Management Product report answers these questions and more, with direct feedback from our 350-veterinarian survey as well as PIMS-based dispensing data as of April 2024. If your company is part of the companion animal pain management market, you won\u2019t want to miss out on the valuable insights in this report. Lynn Fondon\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-24T12:58:03+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint May 24, 2024\",\"datePublished\":\"2024-05-24T12:58:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"},\"wordCount\":181,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\",\"url\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2024-05-24T12:58:03+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint May 24, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"This week we published the latest edition of our annual Pain Management Products report.\u00a0 It\u2019s a fascinating time in the market segment, thanks to the launch last November of Zoetis\u2019 Librela, a monthly monoclonal antibody injection for treating osteoarthritis; and that of Solensia \u2013 the feline equivalent \u2013 in late 2022. This new class of pain management drugs has the potential to revolutionize the treatment of chronic pain.\u00a0 Most veterinarians are already using monoclonal antibodies in their osteoarthritis patients. But how often are they reaching for them?\u00a0 Are they stand-alone treatments, or part of a multi-modal protocol? Will Librela completely replace the use of NSAIDs in treating osteoarthritis? Is Solensia creating a new market, much like Rimadyl did so when it was launched in the 1990\u2019s? Our Pain Management Product report answers these questions and more, with direct feedback from our 350-veterinarian survey as well as PIMS-based dispensing data as of April 2024. If your company is part of the companion animal pain management market, you won\u2019t want to miss out on the valuable insights in this report. Lynn Fondon","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/","og_site_name":"Brakke Consulting Website","article_published_time":"2024-05-24T12:58:03+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint May 24, 2024","datePublished":"2024-05-24T12:58:03+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"},"wordCount":181,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/","url":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2024-05-24T12:58:03+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-may-24-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint May 24, 2024"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/33611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=33611"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/33611\/revisions"}],"predecessor-version":[{"id":33613,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/33611\/revisions\/33613"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=33611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=33611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=33611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}